Inspire Investing LLC Raises Stake in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Inspire Investing LLC increased its stake in Sarepta Therapeutics by 82.9% during the second quarter, owning 27,700 shares worth $474,000.
• Other institutional investors, including UBS AM and Tempus Wealth Planning LLC, also significantly boosted their holdings, contributing to a total of 86.68% of the company's stock being owned by institutional investors.
• Sarepta Therapeutics recently reported $611.09 million in revenue for its quarter, exceeding analyst expectations and marking a 68.4% year-over-year increase.

Inspire Investing LLC grew its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 82.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,700 shares of the biotechnology company's stock after purchasing an additional 12,553 shares during the period. Inspire Investing LLC's holdings in Sarepta Therapeutics were worth $474,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Sarepta Therapeutics by 54.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company's stock worth $29,570,000 after buying an additional 164,041 shares in the last quarter. Tempus Wealth Planning LLC boosted its stake in shares of Sarepta Therapeutics by 475.8% during the 2nd quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company's stock worth $353,000 after acquiring an additional 17,070 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Sarepta Therapeutics by 21.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company's stock worth $14,842,000 after acquiring an additional 155,358 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $11,997,000. Finally, New York State Teachers Retirement System boosted its stake in shares of Sarepta Therapeutics by 3.3% during the 1st quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock worth $5,065,000 after acquiring an additional 2,512 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on SRPT. Piper Sandler boosted their target price on Sarepta Therapeutics to $15.00 and gave the stock a "neutral" rating in a research report on Tuesday, July 29th. Baird R W downgraded shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Bank of America upped their price target on shares of Sarepta Therapeutics to $17.00 and gave the company an "underperform" rating in a report on Wednesday, August 20th. Wolfe Research started coverage on shares of Sarepta Therapeutics in a report on Tuesday, June 17th. They issued a "peer perform" rating on the stock. Finally, Wall Street Zen raised Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Eight research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $34.42.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $22.11 on Monday. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -25.41 and a beta of 0.51. The company's 50 day simple moving average is $19.11 and its 200 day simple moving average is $30.44. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The company had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. During the same quarter in the prior year, the company posted $0.07 EPS. The business's revenue for the quarter was up 68.4% compared to the same quarter last year. On average, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.